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Providing an accurate prognosis in patients suffering from acute CNS
disease is difﬁcult. The extent and location of the primary CNS injury is cru-
cial for mortality and morbidity. Secondary injury adds considerably to the
CNS insult. The prognosis in an individual patient depends on the com-
bination of primary and secondary CNS damage together with systemic
complications. The clinical challenge of an accurate prognosis is therefore
aided by both quantitative techniques, able to estimate the degree of CNS
damage and qualitative techniques, which identify the site of the lesion.
Here the contribution of cerebrospinal ﬂuid (CSF) biomarkers to improving
the prognostic accuracy is reviewed. Firstly current deﬁnitions in biomarker
research are introduced. Secondly the role of the blood brain barrier is dis-
cussed. Thirdly the physiological and anatomical constraints of the CSF are
summarised. Fourthly following an overview on CSF biomarkers, cell–type
speciﬁc CSF biomarkers and more global CSF biomarkers for parenchy-
mal CNS damage are reviewed in detail. The release of these biomarkers
from dying cells is illustrated by a video of a laser–dissected neuron. Fi-
nally, the evidence for improving prognostic accuracy is summarised and
recommendations are made for future biomarker research.
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21 Introduction
Neurocritical medicine provides care to some of the most vulnerable patients.
In most patients the level of consciousness is impaired to the level of coma,
either because of the injury or secondary to deep sedation. Assessing these
patients is clinically challenging. The clinical assessment is helped by stan-
dardised and validated scales targeted at the critically ill patient [1, 2, 3, 4]. A
bad score on these scales implies severe brain damage and is a poor prog-
nostic sign [3, 5, 6, 7, 8]. One problem in giving an accurate prognosis for
an individual patient however is that some patients with a poor score make an
unexpectedly good recovery, whilst others with a very good score suddenly de-
teriorate with subsequent poor outcome. The additional use of CSF biomarkers
may help to improve the prognostic accuracy for an individual patient.
This review is aimed at those working with patients in neurocritical care,
either in a clinical or research context. Firstly, some essential deﬁnitions are
provided. Secondly, the anatomical and physiological basis for the release of
biomarkers into the CSF is reviewed, including a synopsis of the function of
the blood brain barrier (BBB). To illustrate the release of biomarkers from the
cytosol of the damaged brain cells into the adjacent body ﬂuid compartment,
a video of an experimentally damaged neuron is shown. A list of potential
biomarkers and those under current investigation is provided and the most im-
portant CSF biomarkers are discussed in detail. Finally, a summary of the evi-
dence that CSF biomarkers improve prognostic accuracy is given, together with
some recommendations for future biomarker research in neurocritical care.
2 Deﬁnitions
The deﬁnitions presented here were adapted and extended from the experi-
ence with biomarkers in oncology [9] and a recent workshop on biomarkers at
the National Institutes of Health (NIH) on multiple sclerosis [10].
 Biomarker: “a characteristic that is objectively measured and evaluated
as an indicator of normal biologic processes, pathogenic processes, or
pharmacological responses to therapeutic intervention.” [10] Biomarker
may be sub–classiﬁed into:
– Prognostic biomarkers: biomarkers which are associated with a clin-
ical outcome, such as a time–to–event outcome [9].
– Predictive biomarkers: biomarkers which can narrow the choices
between treatment options [9].
– Process biomarkers: biomarkers which allow monitoring of the dy-
namics and activity of pathological features.
– Safety biomarkers: biomarkers which allow evaluation of the safety
of treatments and give an early warning of unwanted side–effects.
3 Surrogate endpoint: “deﬁnes a biomarker that is intended to serve as a
substitute of a clinically meaningful endpoint and is expected to predict
the effect of a therapeutic intervention or the evolution of disease. [10]”
 Clinical endpoint: “deﬁnes a meaningful measure which captures how a
patient feels, functions or survives. [10]” Clinical endpoints may be sub–
classiﬁed into:
– Intermediate endpoint: represents “a clinical endpoint that is not the
ultimate outcome but is nonetheless of real clinical usefulness. [10]
“ (e.g. the GCS or FOUR score)
– Ultimate clinical outcome: represents “a clinical endpoint reﬂective
of accumulation of irreversible morbidity and survival. [10]”
– Time–to–event outcome: The time until a predeﬁned event occurs,
e.g. time to discontinuation of assisted ventilation, time to discharge
from ITU or time to death.
In neurocritical care, where many patients are unresponsive or sedated, a
biomarker provides additional information on damage to the brain parenchyma.
It is my personal opinion that a CSF biomarker should always be regarded as
an extension of the clinical assessment and judgement.
3 Blood–brain barrier
Any substances circulating in the bloodstream may be relatively harmless sys-
temically, but could cause havoc by disturbing brain homoeostasis if they al-
lowed into the ECF. For this reason the brain parenchyma is protected from
the systemic circulation by the BBB. Some basic understanding of the BBB
function is therefore necessary for the balanced interpretation of data on CSF
biomarkers.
The blood–brain barrier (BBB) prevents the unselected diffusion of sub-
stances from the blood into the CSF (Figure 1 A). The blood–CSF barrier (BCB)
in contrast is a ﬁlter which permits substances to diffuse from the blood into the
CSF according to their molecular seize [11]. Strictly speaking one should sepa-
rate between the BBB and BCB function, but for simplicity this is seldom done.
For assessment of the BBB/BCB function the current gold–standard is the
measurement of albumin in the CSF (normal range 144–336 mg/L)1 and serum
(normal range 28.4–53.8 g/L) [12]. Because albumin is not produced intrathe-
cally, all CSF albumin must be derived from the blood by diffusion through the
meninges [13]. An intact BBB/BCB will only allow a small amount of albumin to
diffuse into the CSF. The normal quotient of CSF to serum albumin calculates
1Reference values are reﬂected by many pre-analytical and analytical factors. The reference
values from one laboratory are not necessarily appropriate for another laboratory using different
methods, or for another hospital providing a service to a different patient population.
4Figure 1: (A) A simpliﬁed diagram of the tight blood–brain barrier (BBB) which
separates the blood from the extracellular ﬂuid (ECF) of the brain parenchyma.
The very tight cell membrane prevents proteins from the cytosol diffusing into
the ECF. The less tight blood–CSF barrier (BCB) allows substances to diffuse
from the blood into the CSF.
5Figure 1: (B) Breakdown of the blood–CSF barrier results in leakage of albumin
from the blood into the CSF.
6Figure 1: (C) Cellular death following brain damage leads to disintegration of
the cellular membrane. Biomarkers leak from the cytoplasm into the adjacent
ECF. From the ECF these biomarkers then equilibrate with the CSF.
7Figure 1: (D) Illustrates the situation when both the blood-CSF barrier and the
cell integrity break down. Because of the leakage of ﬂuid and proteins from the
blood into the CSF one would expect a dilution effect, artiﬁcially lowering the
CSF levels of biomarkers released from dying brain cells.
8to 0.0018–0.0074 [12]. A breakdown of the BCB leads to leakage of serum al-
bumin locally into the CSF (Figure 1 B) 2. Consequently the CSF albumin rises
and therefore the CSF to serum albumin quotient increases. The quotient of
the CSF to serum albumin provides a widely accepted tool to approximate the
integrity of the BBB. A CSF to serum albumin quotient > 0.0075 is abnormal3.
Because the CSF is absorbed through the arachnoid villi (which have no bar-
rier function) any substance present in the CSF will enter the blood. There is
no known biomarker speciﬁc for the endothelial cells of the blood vessels in the
brain. This is important to remember because the integrity of the BBB can only
be tested by analysing both a blood and a CSF sample. Any conclusion about
the integrity of the BBB based on an isolated blood sample is questionable.
Irreversible damage to the brain results from death, of a number of brain
cells, either by necrosis or apoptosis causing the cellular membrane disinte-
grate (see video). This leads to leakage of biomarkers from the cytoplasm into
the adjacent ECF (Figure 1 C). From the ECF these biomarkers diffuse into
the CSF from where they can readily be sampled by lumbar puncture or via an
extraventricular or a lumbar drain.
What happens if there is BBB breakdown and additional death of neurons?
Figure 1 D illustrates how albumin and other proteins leaking from the blood
into the CSF dilute the CSF concentration of proteins derived purely from the
brain parenchyma. This is important to note, because high CSF levels of a
biomarker such as neuroﬁlaments [15] (or S100B [16]) in the context of BBB
disruption, for example would still be regarded as a valid measure of damage
to the CNS.
4 Cerebrospinal ﬂuid
Normal CSF is clear and colourless. It consists of 99% of water and has a much
lower protein concentration ( 350 mg/L) 4 than the serum (70,000 mg/L).
The concentration of a CSF biomarker depends on:
1. If derived from the CNS parenchyma:
 Intrathecal production
 Leakage into the ECF
 Diffusion into the CSF
2. If derived from the systemic circulation:
 Serum concentration
2Because there is currently no data on time matched ECF/CSF/blood albumin levels, the rela-
tionship of albumin levels to differential breakdown of the BBB and BCB is unknown.
3Thompson uses the “percentage albumin transfer” (
CSFAlb
SerumAlb  100 instead [14]. A percentage
albumin transfer >0.7% is indicative of leakage of albumin from the serum through a damage BBB.)
4Please note that this value refers to the CSF total protein concentration which is higher then
the CSF albumin concentration of 144–336 mg/L mentioned above.
9 BBB integrity
 Hydrodynamic radius
About 70% of CSF is derived from the choroid plexus by ﬁltration from the
blood [17, 18]. The highest ﬁltration rate ( 40 mL per hour [19]) occurs nat-
urally at night, in the recumbent position with increased hydrostatic pressure,
which probably accounts for clinical symptoms such as headache and nausea
suffered in the morning by patients with hydrocephalus. The remainder of the
CSF comes from the ECF of the brain parenchyma and through the meninges
and the blood–nerve barrier at level of the nerve roots. The CSF is modiﬁed
on its passage from the ventricles to the lumbar sac and this is inﬂuenced by
the CSF ﬂow rate [20]. As a rule of thumb the concentration of proteins derived
from the plasma is highest in the lumbar CSF and shows a rostro–caudal gra-
dient, because of diffusion through the blood–nerve barrier along the length of
the spinal cord.
Proteins derived from the brain parenchyma, called by some authors brain–
speciﬁc proteins (BSP) or CNS–speciﬁc proteins, only make up about 10% of
the total CSF protein content [11]. Concentrations of some of these BSPs are
higher in the ventricular CSF and others higher in the lumbar CSF [13]. With the
availability of microdialysis as a clinical and research tool it may be possible in
future to obtain longitudinal (e.g. hourly) samples from the ECF and ventricular
and lumbar CSF. Such samples would be extremely valuable for future CSF
biomarker research.
5 CSF Biomarkers
Biomarkers can be put in to 6 broad categories, of which cell–type speciﬁc
biomarkers are most relevant for prognosis in neurocritical care because they
allow for a precise estimate of the amount of CNS tissue destruction.
1. CSF pigments
2. CSF metabolic biomarkers
3. CSF cell–type–speciﬁc biomarkers
4. CSF biomarkers for widespread CNS damage
5. CSF free–radicals and biomarkers of oxidative stress
6. CSF biomarkers for inﬂammatory/immunological processes
5.1 Pigments
The clear CSF changes colour with the addition of substances such as biliru-
bin (yellow) or haemoglobin (red) [21]. Spectrophotometry allows quantitative
10measurement of pigments in the CSF [22, 23]. Because of the continuous con-
version of haemoglobin to bilirubin, one expects oxyhaemoglobin levels to de-
crease as bilirubin levels increase following e.g. a subarachnoid haermorrhage
(SAH). A secondary increase in CSF oxyhaemoglobin suggestive of micro–
rebleeds, was observed in SAH [24]. Micro–rebleeds may be too small to be
visible on CT, so the quantiﬁcation of CSF pigments may allow investigation of
the occurrence and prognostic implications of micro–rebleeds.
5.2 Metabolic biomarkers
These biomarkers represent the intermediate- and end–products of the metabolic
pathways. A very small sample volume can rapidly be analysed. The basic
metabolic pathways are shared by most cell types and are therefore good in-
dicators of global impairment, but are not speciﬁc for any particular cell type
or pathological process (see Table 1). CSF glucose and pyruvate are routinely
measured. CSF lactate is also relevant in certain conditions. During ischaemia
the cellular metabolism switches from the aerobic to the anaerobic pathway
leading to an increase of lactate and decrease of pyruvate which indicates a
lack of O2 supply. Metabolic biomarkers were also amongst the ﬁrst to be in-
vestigated in the extracellular ﬂuid (ECF) using microdialysis [25].
5.3 Cell–type speciﬁc biomarkers
Cell–type speciﬁc biomarkers are proteins, lipids or circulating nucleic acids
exclusively expressed by a speciﬁc cell–type, for example, neuroﬁlaments are
only expressed in neurons and their axons [15]. This is illustrated by a video
on the Journal’s website.
Link out to the video clip about here]
Caption to the video clip to be shown on the Journal’s website:
the video shows a dorsal root ganglion with its axon in a culture
dish located within a laser–dissection microscope. A laser beam
is directed to the cell membrane of the neuron. As the membrane
is cut open the content of the cytoplasm is released into the cul-
ture media. Next, the axon is severed by the laser beam. All the
substances released into the culture medium can potentially be
quantiﬁed and used as biomarkers.
In the brain, cell–type speciﬁc biomarkers are released into the extra–cellular
ﬂuid (ECF) following any form of cellular damage. From the ECF these biomark-
ers diffuse into the cerebrospinal ﬂuid (CSF) and thence into the systemic cir-
culation (Figure 1 C). Figure 2 illustrates how neuroﬁlaments one(one example















































Figure 2: Neuroﬁlaments are released into the extracellular ﬂuid (ECF) follow-
ing axonal disintegration. From the ECF Nfs equilibrate with the adjacent body
ﬂuid compartment. Quantiﬁcation of Nfs is therefore possible from the cere-
brospinal ﬂuid (CSF) [26, 27, 28], blood [29, 30] and amniotic ﬂuid [31]. The
degree of axonal degeneration is related to the amount of Nf measured in these
body ﬂuids. For this reason body ﬂuid Nf levels permit estimation of the amount
of axonal degeneration. Axonal degeneration is relevant because axonal loss is
irreversible and a leading cause of persistent disability in an individual patient.
12A list of established and emerging CSF biomarkers is presented in Table 1.
Only few are cell–type speciﬁc; most are indicative of more widespread dam-
age to the CNS parenchyma.
13Table 1: Established and potential CSF biomarkers and their cellular sources for acute CNS
damage, assuming a normal PNS.
CSF Neuron Astro- Micro- Oligoden- Choroid Blood
Biomarker & Axon cyte glia drocyte plexus










-trace (+) + 5
Clusterin + + + +
Cystatin C + +
EDG-8 +
FABPs + + + + +
FFA + + + + +
Ferritin + +
GFAP +
Glucose + + + + +
Glutamate + + + + +
HK6 +
HNE + + + + +
Hypocretin–1 + 6
Isoprostanes + + + + +
Lactate + + + + +
MAG +
MBP +
MDA + + + + +
MOBP +
MOG +
NAA ++ + + +
NCAM + +
NOx + + + +
NSE + +




5mainly derived from meningeal cells
6from hypothalamic neurons
14PrPc +
Pyruvate + + + + +
S100B ++ +
SFas (sCD95) +
Tau + + + +
Ubiquitin + + + + +
Vimentin + + +
Neuroﬁlaments Neuroﬁlaments (Nf) are the key building blocks of the axonal
cytoskeleton. The Nf protein is a heteropolymer composed of four subunits: a
light (NfL), a medium (NfM), and a heavy (NfH) chain [32], and –internexin
[33, 34, 35]. Nf are almost exclusively expressed in neurons and axons [27, 15].
Following damage to the neuron and/or axon, the cytoplasmatic contents are
released into the extracellular ﬂuid (ECF) (Figure 2 and video). From the ECF
Nf diffuse into other body ﬂuid compartments including the cerebrospinal ﬂuid
(CSF) (Figure 1 C).
High–throughput analysis of Nfs is possible using enzyme–linked immune
assays (ELISA). In-house ELISAs have been developed for NfL and NfH [26,
27, 28, 30]. These assays are robust and have been cross–validated [36, 37].
A commercial ELISA kit for quantiﬁcation of the phosphorylated Nf heavy chain
(pNfH) has recently become available (Chemicon, catalogue number NS170).
CSF Nf levels have been studied most extensively in patients suffering from
a SAH, all studies revealing comparable results [27, 38, 36, 39, 40]. Following
the bleed, CSF NfH and NfL levels are considerably elevated in all SAH patients
when compared to controls. One longitudinal UK study suggested that there
may be a secondary increase of CSF NfH levels [38]. This was conﬁrmed
in a subsequent longitudinal US study and interpreted as the consequence
of secondary brain damage caused by delayed cerebral ischaemia. The study
also demonstrated that patients with a poor outcome on the 6–month GOS (1 to
3) showed a secondary increase of ventricular CSF NfH levels about four days
after the bleed [39]. Nyl´ en et al. went on to show in a cross–sectional study
that lumbar CSF NfL levels 10–14 days after the bleed were signiﬁcantly higher
in those patients with a bad recovery (GOSE 1 to 4) compared to those with
a favourable outcome (GOSE 5 to 8) [40]. CSF NfH and NfL levels correlated
with the initial severity of the injury [39, 40].
Norgren et al. showed that CSF NfL levels were elevated in 5/6 patients with
stroke [28]. In a longitudinal study on 34 patients with a minor stroke, we found
a weak correlation between CSF NfH levels and the modiﬁed Rankin score at
discharge (unpublished data).
Ros´ en et al. showed that CSF NfL levels taken an average of 17.5 days
after cardiac arrest predicted the one–year outcome on three scales: GOS,
minimental state examination (MMSE) and activity of daily living (ADL) [41]. In
this particular study the scoring on the GOS was inverse to convention [2, 42],
thus explaining the positive correlation of the CSF NfL levels with the GOS
(R=0.79) rather than the expected negative correlation [41].
15Glial ﬁbrillary acidic protein Glial ﬁbrillary acidic protein (GFAP) is a key
building block of the cytoskeleton of the astrocyte. During astrocytosis this cy-
toskeleton rapidly reshapes and the tightly packed GFAP polymer loosens up
within minutes, thus exposing more epitopes for recognition by anti–GFAP an-
tibodies. This explains the extensive immunohistochemical staining with anti–
GFAP antibodies of astrocytosis. Importantly, astrocytes are particularly vul-
nerable to ischaemia [43, 44, 45] and the measurement of GFAP released dur-
ing astrocytosis and astroglial disintegration provides a tool for monitoring glial
pathology.
A number of in–house GFAP ELISAs have been developed [46, 47, 48, 49,
50] and a commercial kit is available through Biovendor (Heidelberg, Germany,
Cat No. RD 192072200).
Nylen et al. found that CSF GFAP levels were elevated in patients with
vasculitis [51]. Inspection of Table 2 in reference [51] suggests that CSF GFAP
levels are particularly high in patients with systemic lupus erythematosus (SLE)
who also presented with focal neurology.
Gurnett et al. found levels of CSF GFAP (but not CSF NSE) to be increased
in children following an epileptic seizure. CSF GFAP levels were highest in
children with symptomatic epilepsy and prolonged seizures [52].
CSF levels of GFAP were found to be elevated in patients with SAH [53].
A subsequent longitudinal study showed CSF GFAP levels to be pathological
in 93% of all samples [54]. By comparing non–survivors with survivors, signif-
icantly higher CSF GFAP levels were found for the former on day 2 and again
on days 6 and 7 following the bleed. A simple model for the interpretation of
CSF GFAP levels in patients with SAH was proposed based on these results
(Figure 3). Given the number on studies on serum GFAP levels in patients with
SAH and stroke [55, 55, 56, 57, 58] there is a lack of data on CSF GFAP.
Myelin proteins Myelin proteins speciﬁc for the CNS and PNS consist of sev-
eral hydrophobic proteins. Myelin–associated glycoprotein (MAG,  100kDa)
is expressed both in the CNS and PNS and accounts for about 0.1-1% of total
myelin protein [59]. Due to alternative mRNA splicing, two MAG isoforms (L–
MAG, S–MAG) exist. Myelin–associated oligodendrocytic protein (MOBP) is a
small protein present only in oligodendrocytes. Myelin basic protein (MBP)
is expressed in the CNS and PNS in a variety of isoforms due to alterna-
tive splicing and an even larger number of post–translational modiﬁcations.
Myelin/oligodendrocyte glycoprotein (MOG) is a transmembrane protein in the
CNS. Oligodendrocyte/myelin glycoprotein (OMgp) is a 120 kDa glycosylated
extracellular molecule in the CNS. The proteolipid protein belongs to the tetraspanins
and is one of the most hydrophobic proteins known [59]. Of all these myelin
proteins, it is mainly myelin basic protein (MBP) which has been measured in
the CSF.
Myelin basic protein (MBP) Myelin basic protein (MBP) is encoded on chro-
mosome 18q23 and has 170 amino acid residues and a molecular weight of
16Figure 3: A model how longitudinal CSF GFAP levels may help improving the
prognostic accuracy in patients with SAH. CSF GFAP levels within the dark-
grey area are suggestive of a bad prognosis based on the severity of the pri-
mary brain injury, whilst levels in the light–grey area suggest poor prognosis
due to secondary brain damage. (Figure reprinted with permission from refer-
ence [53] )
1718,500 Da. MBP is a major constituent of the myelin sheath of oligodendro-
cytes and Schwann cells. MBP–related transcripts are also present in the bone
marrow and immune system, arising from “Golli–MBP” with 3 additional exons
located upstream to the classical MBP.
Due to its basic properties the quantiﬁcation of MBP is challenging. Nu-
merous research groups have developed in–house methods and a range of
commercial assays are available.
CSF MBP has been measured in patients with TBI [60, 61, 62, 63], hy-
drocephalus [64, 65, 66, 67], SAH [68], brain tumours and metastatic brain
disease [69, 70, 71], asphyxia in children [72, 73], following chemotherapy
[74, 75, 76, 77], stroke [62, 70, 78, 79, 80], encephalitis [70, 81, 82, 83, 80, 73],
epilepsy [66], and following neurosurgery in patients with TBI and tumours [84].
MBP has probably been investigated most intensively in the CSF of patients
suffering from multiple sclerosis (for review see reference [85]).
Noseworthy et al. were the ﬁrst to describe a relationship between CSF
MBP levels and outcome (GOS at 7 days, 3 months and 6 months) in patients
with severe closed head injury [63]. In patients with SAH, CSF MBP levels were
related to the occurrence of vasospasm–related delayed ischaemic neuronal
deﬁcit (DIND), infarct size and the 3 months GOS in one study [68]. In stroke
CSF, MBP levels were related to the short–term outcome [78]. In asphyxi-
ated full–term infants, increased CSF MBP levels were related to poor outcome
(death or cerebral palsy at one year) [72]. In children with hydrocephalus and
seizures, Levin et al. did not ﬁnd CSF MBP levels to be of prognostic value
[66].
Circulating nucleic acids Following cellular disintegration by apoptosis or
necrosis, DNA and RNA are released into the blood [86]. Some cells may even
to actively secrete DNA. Several methodological issues still need addressing,
but oncology and neonatal medicine already use circulating nucleic acids for
diagnostic and monitoring purposes [87]. Lam et al. investigated circulating
nucleic acids in 44 patients suffering from stroke and found them to be a bet-
ter predictor of outcome than S100B on the 6 months modiﬁed Rankin scale
[88]. Circulating nucleic acids speciﬁc for different cell types could become an
interesting future CSF biomarker.
5.4 CNS speciﬁc biomarkers
There are a number of CSF biomarkers in Table 1 which are not exclusively
expressed by one single cell–type, but are nevertheless valuable in the as-
sessment of damage to the CNS. Some of these may even be present in the
serum due to systemic release, but if measured from the CSF they still allow
for estimation of CNS damage.
Neuron speciﬁc enolase (NSE) Enolase is one of many glycolytic enzymes
and consists of three subunits (,  and ) [89]. In the CNS the  and 
18isoforms are mainly localised within the neurons and therefore called neuron-
speciﬁc enolase (NSE) [90]. Generally, NSE levels are now mainly used as a
tumour marker for lung cancer [91].
Earlier studies on CSF NSE levels found them to be elevated in patients
with acute encephalitis, meningitis, CVA, acute polyradiculoneuritis and brain
tumours (see Figure 2 in reference [92]). This ﬁndings were later conﬁrmed
and the list extended to brain tumour and epilepsy [93]. This makes CSF NSE
levels important in neurcritical care.
Some authors found CSF NSE to be increased in children and adults fol-
lowing an epileptic seizure, particularly after a prolonged seizure [94, 95, 96],
but others did not [52, 97, 98]. Comparing CSF and serum NSE levels in a
heterogeneous group of patients with meningitis, acute brain injury with im-
paired levels of consciousness, neurocysticerosis and normal controls, Lima et
al. found the former to be related to the GOS at discharge or death [99]. In one
study of patients with GBS, high CSF NSE values predicted a longer disease
duration [100]. Following cardiac arrest, elevated CSF NSE levels found 72
hours after the event were related to functional outcome [101].
Pleines et al. showed CSF NSE levels to be considerably elevated in TBI
patients for the ﬁrst 3 days following the event and they slowly decreased over
the next 2 weeks [102]. The mean CSF NSE levels correlated with the contu-
sion size on CT, but did not correlate with outcome on the GOS [102]. Similarly
Ross et al. did not ﬁnd CSF NSE levels to correlate with the GOS, APACHE II
or ISS [103].
CSF NSE levels were also markedly elevated in children with TBI compared
to controls [104]. A secondary increase of CSF NSE levels was observed in
4 of 5 children with inﬂicted TBI (iTBI) (see Figure 2 in reference [104]). The
authors note that iTBI in children is frequently associated with violent shaking
and/or impact with a hard surface, in addition to delayed presentation to health
care professionals, potentially leading to hypoxia and ischaemia. This leads to
the suggestion that delayed neuronal death may be an important feature in iTBI
[104]. This observation is consistent with an earlier study in asphyxiated infants
which correlated elevated CSF NSE levels with outcome (death or cerebral
palsy at 1 year) [72]. The Pittsburgh group then went on to investigate the
prognostic value and found CSF NSE levels to correlate with the 6–months
GOS [105]. However, their subgroup analysis showed that this was only the
case in children over the age of four [105].
S100B Originally isolated from the bovine CNS by Moore in 1965 [106], the
protein was named S100 because of its solubility in 100% saturated ammonium
sulphate at neutral pH. S100B is now known to belong to a large family of S100
proteins [107]. S100B is coded on chromosome 21q22.3 [108] and consists of
91 amino acids and its molecular weight corresponds to 10–12 kDa. S100B is
a water–soluble, cytoplasmic protein and contains 2 EF–hand calcium–binding
domains (4 Ca2+ per dimer). The S100 proteins also bind Zn2+ and Cu2+
[109].
19For quantiﬁcation of S100B there are a number of in–house developed
ELISAs [110, 92, 111, 112, 80] and a range of commercially available ELISAs
such as the Can Ag S100 EIA (Can Ag Diagnostics AB, Gothenburg, Swe-
den), the ELISA NEXUS CXTMS100 (Syn X Pharma INc., York, UK) and the
Sangtec R 100 IRMA, Liaison R Sangtec 100 and Sangtec 100 ELISA from Di-
aSorin AB (Bromma, Sweden) [113]. S100B levels are probably now most
frequently used as a tumour marker for malignant melanoma [114, 115].
Earlier work on the CSF by Michetti et al. showed that S100B levels were
elevated in patients with acute MS, acute encephalomyelitis, compression of
the spinal cord and intracranial tumours [112]. The results were comparable to
the observations by Sindic et al. who additionally found elevated CSF S100B
levels in patients with stroke and SAH [111]. The spectrum of neurological
diseases with elevated CSF S100B levels was broadened by Mokuno et al.
to include patients with acute encephalitis, meningitis, SAH, CVA, multi–infarct
dementia, Parkinson’s disease, oral dyskinesias, cervical spondylosis, acute
multiple sclerosis, acute and chronic polyradiculoneuritis and brain tumours
(see Figure 2 in reference [92]). The ﬁndings in CVA were consistent with a
later study [80]. Epilepsy has also been added to the list of acute neurological
disorders with elevated CSF S100B levels [80, 116].
Over the last decade, a large number of studies has been published on
serum S100B levels, mostly using the Sangtec R 100 IRMA (for reviews see
[117, 16, 118, 119]). Less data is available on CSF S100B levels which, as
one study showed, did not correlate with those found in the serum [120]. The
original work by Sindic et al. included a small number of patients with clinical
follow–up data and longitudinal CSF S100B levels suggesting that in herpes
encephalitis and transverse myelitis high CSF S100B levels may be a poor
prognostic sign (Table 2 in reference [111]).
Pleines et al. showed that CSF S100B levels were considerably elevated
in TBI patients for the ﬁrst 3 days following the event and they then slowly
decreased over the next 2 weeks [102]. CSF S100B but not CSF NSE levels
correlated with the contusion lesion size on CT and the GOS. Kay et al. showed
elevated CSF S100B levels in TBI, but there was no correlation with outcome
data [121, 122]. Hayakata et al. showed CSF S100B levels to be elevated in
severe TBI (GCS < 8) and particularly in those with high ICPs [123]. Peak CSF
S100B level were strongly correlated with the ICP. Importantly CSF S100B lev-
els were higher in patients with unfavourable outcome compared to those with
favourable outcome [123]. In children with iTBI CSF S100B levels correlated
with the 6–months GOS [105].
High CSF S100B levels were described in patients with SAH [120]. In an-
other study on SAH, CSF S100B levels on admission were also elevated but
did not correlate with either injury severity (GCS) or outcome (GOS) [124].
Analysing the longitudinal proﬁle of the same cohort, Kay et al. showed that
the peak CSF S100B levels over a 7–day observation period correlated with
the 3–month GOS [125].
20Tau This microtubule-associated protein tau, also known as neuroﬁbrillary
tangle protein and paired helical ﬁlament-tau (PHF-tau). Tau is encoded on
chromosome 17 and due to alternative splicing of the mRNA, six isoforms with
a molecular weight of 48 to 68 kDa [126] exist in the human brain. Tau pro-
motes microtubule stability and is used as a biomarker for neuro–axonal de-
generation.
For quantiﬁcation of tau most laboratories now use the hTau ELISA from
Innogenetics (Ghent, Belgium).
Vandermeeren et al. were the ﬁrst to report elevated CSF hTau levels in
5/11 patients with GBS [127]. Jin et al. then reported CSF hTau levels to be
higher in patients with poor outcome (Hughe’s functional grading scale score
2–5) compared to those with good outcome at 6 months [128]. Both studies
contrasted with a small study by S¨ ussmuth et al., who found CSF hTau levels to
be normal in GBS (n=5) [129]. All three groups used the same hTau ELISA from
Innogenetics [127, 128, 129], suggesting that the different results may have
been due to pre–analytical and clinical. Inspection of Figure 1 in reference [128]
shows a bimodal distribution of CSF hTau levels for those patients with good
outcome and it would be interesting to know from all the studies whether those
patients with low CSF hTau levels had predominantly demyelinating pathology
on electrophsysiological studies. Additionally, distal versus proximal axonal
damage may account for the discrepancy [130]. Ost et al. found CSF tau
levels to correlate with the 1–year outcome following TBI on the GOS, NIHSS
and the Barthel daily living index [131].
Zemlan et al. developed antibodies directed against 30 to 50 kDa cleaved
tau (c-tau) [132]. They showed that the antibodies (ctau7, cTau8, cTau12) bind
to the interior portion (Pro251–MET419) of the tau sequence with the N- and
C–terminal amino acids being cleaved. The highest CSF tau levels were ob-
served in patients with TBI when compared to MS, NPH or non–neurological
controls [132]. Subsequently the authors measured CSF c-tau in patients with
TBI, neurological- and non–neurological controls [133]. Initial c-tau levels were
about 40,000-fold higher in the CSF of patients with TBI compared to either
control group. C-tau and the GCS were independent predictors of the clinical
outcome (GOS on discharge). The sensitivity/speciﬁcity limits for predicting an
unfavourable outcome were 92%/94% for c-tau and 50%/100% for the GCS
[133]. Quantiﬁcation of c-tau opens an interesting future possiblity for CSF
biomarker studies.
Amyloid beta peptide (ABP) The  700 amino acid large amyloid precur-
sor protein (APP) is cleaved at the  and  sites by secretases into amyloid
sequences of 40/43 residues (ABP). The numbers behind the ABP refer to the
cleavage site of the protein fragment (e.g. ABP 1-42). The amyloid beta peptide
(ABP) is important in the pathogenesis of Alzheimer’s disease. Nicoll et al. sug-
gested a link between ABP deposition in the brain of patients with head injury
and presence of the APOE epsilon4 allele [134]. In the CSF decreased levels
of ABP 1-42 provide valuable information for the differential diagnosis of neu-
21rodegenerative dementias [135]. CSF ABP has also been measured in patients
with ischaemic stroke [136], SAH [125, 124], TBI [121, 122, 137, 138, 139] and
acute bacterial meningitis [140].
In SAH both the CSF ABP 1-40 and 1-42 fraction were lower compared
with CSF ABP levels in controls [125, 124]. The maximum decrease in the
CSF ABP concentration correlated with the 3–months outcome in a longitudinal
study [124].
In TBI, Kay et al. described the CSF ABP 1-40 and 1-42 as remaining low
for at least 5 days following the injury [122]. There was no relationship with the
GOS. In contrast, Franz et al. who found CSF ABP 1-42 levels to distinguish be-
tween good (GOS 4-5) and bad (GOS 1-3) outcome with a sensitivity of 100%
and a speciﬁcity of 82% [138]. In a subsequent scientiﬁc exchange, Blennow
and Nellg˚ ard make the important point that CSF ABP levels are about 5–fold
higher in lumbar compared to ventricular CSF in patients with Alzheimer’s dis-
ease [141]. In their reply, Franz et al. conﬁrmed this point for their TBI cohort,
showing about 2–fold higher ABP 1-42 levels in the lumbar compared to the
ventricular CSF though the latter group had a worse outcome, potentially intro-
ducing a sample bias. All three studies [122, 138, 141] contrast with an earlier
report on showing an increase of CSF ABP 1-42 levels in TBI patients [142].
Apolipoprotein E Polymorphism of the apolipoproteins E gene (APOE) inﬂu-
ences the risk of the development of the sporadic from of Alzheimer’s disease
(AD) and is a risk factor for more severe disease in almost every neurological
disorder except GBS [143, 144, 145]. In patients suffering from a head injury,
Teasdale et al. was ﬁrst to show that the presence of the APOE 4 allele was
associated with a signiﬁcantly higher risk of mortality [146].
In the CNS ApoE is relevant for transport of cholesterol and lipids [147]. In
TBI a decrease in CSF apoE levels was observed [121, 122], but CSF apoE
levels did not correlate with the GOS [122]. Following SAH CSF apoE levels
were also reduced, albeit to a lesser degree than in TBI [124, 125], and corre-
lated with the 3–months GOS [125]. In ischaemic stroke CSF apoE levels were
no different from the control group [136].
Hypocretin-1 Hypocretin-1 (synonymous orexin-A) is a neurotransmitter re-
leased from the posterior hypothalamus, and is relevant to the modulation of
various different psychological functions [148, 149]. Since Lin et al. recognised
that CSF hypocretin-1 levels were decreased in the CSF of patients with nar-
colepsy, this small peptide has been studied in a large range of neurological
conditions (for a review see [150]). Rejdak et al. showed in a longitudinal study
that CSF hypocretin-1 levels were decreased in patients with acute brain injury
(TBI and SAH) and remained undetectable in two patients with a destructive
lesion of the thalamus/midbrain [151]. Because excessive fatigue or daytime
sleepiness has been reported following a SAH [152], the authors suggested
that a deﬁcient hypocretin/orexin system may in part have been responsible for
abnormalities in the sleep–wake cycle following acute brain injury. The ﬁndings
22were consistent with those of a larger cross–sectional study on patients suffer-
ing from TBI [153]. Another small longitudinal study on SAH patients (n=15)
conﬁrmed that CSF hypocretin-1 levels decreased after SAH and were unde-
tectable in those with a GCS of less than 8 on admission [154]. This was in
line with a further study on 15 patients with SAH, with a secondary decrease
and particular low CSF hypocretin-1 levels in those who developed delayed
ischaemic neuronal deﬁcit (DIND) [155]. In 4/6 patients suffering from a para-
neoplastic encephalitis (positive for anti–MA antibodies) and one patient with
Hashimoto’s encephalopathy, excessive daytime sleepiness was also associ-
ated with undetectable CSF hypocretin-1 levels [156, 157]. Remarkably, the
diurnal variation of CSF hypocretin-1 levels (about 4%) has been described in
healthy controls, suggesting that sampling time is of minor importance [158].
Alpha spectrin Two independent studies demonstrated that CSF Alpha-II
spectrin levels were elevated in patients with severe TBI (GCS<8) [159, 160].
The longitudinal data analysis of the study by Cardali and Maugeri showed
that those patients who maintained high CSF levels of alpha-II spectrin and
spectrin breakdown products (SBDPs) had a poorer outcome on the 6–months
GOS [159]. In an experimental rat ischaemia model CSF -spectrin cleavage
products were also detectable [161]. These authors point out the widespread
distribution of -spectrin in essentially all non–neuronal cells [162] makes it
unlikely that CSF -spectrin will ever become a speciﬁc biomarker for brain in-
jury [161]. Nevertheless Pineda et al. demonstrated a differential time proﬁle
for calpain and caspase-3 mediated SBDPs [163]. In their study SBDPs were
related to the 6 months GOS.
Cytochrome C Cytochrome C has been used as a biomarker for apoptosis.
Statchell et al. showed CSF cytochrome C levels to be increased in children
with iTBI compared to controls [164].
Taurine The amino acid taurine is currently best known as an additive to en-
ergising drinks. Experimentally taurine was released during cellular oedema,
e.g. from astrocytes, and possessed anti–oxidant properties. Seki et al. demon-
strated that CSF taurine levels were marginally increased in the CSF of patients
with TBI when compared to patients with normal pressure hydrocephalus [165].
In an experimental TBI model in rats, Stover et al. showed that CSF taurine
levels were increased about 8 hours after the injury [166]. The same group de-
scribed an increase of CSF taurine levels in patients with subdural or epidural
haematomas, contusions and generalised brain oedema [167].
NT-proBNP N-terminal (NT)-pro brain natriuretic peptide BNP) was shown to
be elevated in a longitudinal study on ventricular CSF from TBI patients, but
CSF NG-proBNP levels were not correlated with the 3–months GOS [168].
23Ubiquitin Majetschak et al. showed that CSF ubiquitin levels continued to
rise until death in 3 TBI patients, but recovered in 3 survivors from TBI [169].
The substantiated their ﬁndings by an experimental TBi study in pigs, showing
that the biological half life of ubiquitin was about 1.3 hours. Contamination of
the CSF by erythrocytes and consequent lysis accounted for about 15% of the
CSF ubiquitin levels [169].
14-3-3 The 14-3-3 proteins ( 30 kDa) are highly homologous, dimeric pro-
teins, expressed in almost all eukaryotic cells from yeast to humans [170]. In
humans one separate gene encodes for each of the seven isoforms (, , , ,
, , ) [171]. Five major isoforms are found in the CNS, named  to . 14-
3-3 is phosphorylated to 14-3-3, and 14-3-3 is phosphorylated to 14-3-3.
14-3-3 proteins are involved in the regulation of the cell–cycle, cell signalling,
intracellular trafﬁcking and shaping of the cytoskeleton [170, 172, 173]. Since
Boston et al. ﬁrst described the presence of 14-3-3 in the CSF [174], the 14-
3-3 isoform has been most commonly used as a CSF biomarker. 14-3-3
is expressed in neurons, astrocytes, oligodendrocytes, and microglia [175]. To
the best of my knowledge attempts to develop an ELISA for quantiﬁcation of 14-
3-3 isoforms has so far not been successful. This may be due to the epitopes
of the different isoforms being crypotogenic, and/or the difﬁculties in raising
antibodies against such ubiquitous proteins. Most laboratories currently use
immunoblotting techniques for detection of 14-3-3 as described elsewhere
[176].
CSF 14-3-3 is most frequently used as a biomarker in the differential diag-
nosis of Creuzfeld–Jakob disease [177] but, as with all other proteins 14-3-3 is
essentially released following cellular damage. CSF 14-3-3 has been reported
in patients with GBS [178], Hashimoto’s encephalopathy [179, 180], meningitis
and encephalitis [181, 175], stroke–like episodes [175] and transverse myelitis
[182].
Nestin Nestin belongs to the intermediate ﬁlaments and is found in CNS pro-
genitor cells. One group found CSF nestin levels to be decreased following
asphyxia [183].
Albumin Ischaemia–modiﬁed albumin has been found in the serum in pa-
tients with stroke [184, 185, 186]. It can also be detected virtually whenever a
small amount of hypoxia (e.g. anaerobic metabolism) occurs, including physical
exercise [187, 188]. Ischaemia–modiﬁed albumin has not yet been investigated
in the CSF. As discussed further down the timing of sampling is important for
interpretation of the data.
245.5 Oxidative stress and free radicals
Oxidative stress occurs when the physiological balance between oxidants and
antioxidants is shifted towards the former. The production of oxidants such as
free radicals is increased in patients with ischaemic brain damage [189]. This
increase of free radicals causes oxidative stress which compounds existing
brain damage. Therefore biomarkers of oxidative stress have the potential to
allow monitoring of secondary brain injury and may be relevant for prognosis.
Following ischaemia some Ca2+–activated enzymes such as cyclo–oxygenase
(COX) and phospholipase A2 produce oxygen free radicals, whilst others such
as nitric oxide synthase (nNOS and iNOS) produce nitric oxide (NO). Iron is
another important source of free radicals (OH . via the Fenton reaction), partic-
ularly after haemorrhagic brain injury.
Nitric oxide (NO) The methodological challenge is that free radicals cannot
readily be measured in vivo. The biological half–life of NO is less then 5 sec-
onds, therefore downstream metabolites need to be quantiﬁed instead. For
example, the NO metabolites NO2 and NO3 (commonly denoted as NOx for
NO metabolites) can be measured in the CSF using a high–throughput tech-
nique [190, 191]. CSF NOx levels did distinguish survivors from non–survivors
in one study [38]. For a comprehensive review on NO, the reader is referred to
more substantial reviews [192, 193, 194].
Excitatory amino acids Excitatory acids such as glutamate are neurotoxic if
released in excess. There is an excellent review by Meldrum and Garthwaite
on glutamate exitotoxicity [195].
Palmer et al. found that CSF glutamate levels increased for 3 days follow-
ing TBI. CSF glutamate levels were about 7 M, which was considered to be
sufﬁciently high to cause further excitotoxicity [196]. Elevated CSF glutamate
concentrations were also found by Baker et al. in a separate longitudinal study
on TBI. The results were consistent with those by Zhang et al. who found CSF
glutamate (and aspartate) levels to be elevated in TBI compared to neurological
control patients and to correlate with the 3–months GOS [197]. Another lon-
gitudinal study found that the highest CSF glutamate levels peaked about 48
hours after TBI [198]. The same group then went on to describe an increase of
CSF glutamate levels in patients with subdural or epidural haematomas, con-
tusions and generalised brain oedema [167]. CSF glutamate levels were also
increased in children with TBI [199]. These ﬁndings are in line with those ob-
tained for CSF glutamate in an experimental study on TBI in rats [166].
Lipid peroxidation For lipid peroxidation, the unstable aldehydes malondi-
aldehyde (MDA) and 4-hydroxynonenal (HNE) have been measured alongside
thiobarbituric acid-reactive substances (TBARs). MDA has been related with
stroke size and outcome [200].
25Free fatty acids (FFA) Elevated levels of FFAs have been found in the CSF of
patients with stroke, TBI, SAH. CSF FFAs levels were related to injury severity
and outcome (for review see reference [201]).
Isoprostanes Isoprostanes are non–enzymatically synthesised from polyun-
saturated fatty acids such as e.g. arachidonic acid [202]. They are released in
their free form by phospholipases [203]. Importantly isoprostanes are relatively
stable [203, 204]. F2-isoprostanes appear to be more reliable biomarkers for
lipid peroxidation than e.g. MDA. Importantly, they are not only a metabolic
product, but also have important biological functions [203]. For example the
15-F2t-IsoP is an important vasoconstrictor, alongside 9-epi-15-F2t-IsoP and
15-epi-15-F2t-IsoP, with the E–series probably being even more potent vaso-
constrictors (e.g. 15-E2t-IsoP) [205]. CSF levels of F2–isoprostanes have
recently been measured in patients with SAH [206]. Peak and mean CSF
F2-isoprostane levels correlated strongly with poor outcome, although these
correlations were less impressive for plasma F2–isoprostane levels [206]. In
patients with severe TBI (GCS<8) CSF F2-isoprostane levels peaked on day
one after the injury and were signiﬁcantly higher in males than females, sug-
gesting that the degree of lipid peroxidation differs with gender in TBI [207].
In children suffering from severe TBI, CSF F2-isoprostane levels were higher
compared to control CSF when [208]. Wagner et al. showed in a longitudinal
study that CSF F2-isoprostane levels on day one correlated inversely with the
6–months GOS in women suffering from TBI [209].
Fatty acid binding proteins (FABPs) These are  15 kDa proteins impor-
tant for the uptake, transport and metabolism of fatty acids. Initially isolated
from the heart muscle (H-FABP), they were subsequently found in many other
cells including the brain [210]. In fact, FABs are present in all cells utilising
fatty acids. Because they are not cell–type speciﬁc, and because their small
molecular size allows for easy passage into the CSF, elevated CSF levels may
be artefactual due to systemic involvement [211]. However, two studies inde-
pendently found serum FABPs to be better prognostic indicators than serum
S100B in patients with stroke [212, 213].
5.6 Inﬂammatory and immunological biomarker
The brain is an immunoprivileged organ. Inﬂammatory processes in brain tis-
sue are tightly controlled [214]. The spectrum of CSF biomarkers relevant to
the inﬂammatory and immunological diseases of the CNS is far beyond the
scope of this review. Widening the spectrum from neurocritical care to the gen-
eral intensive care unit, such biomarkers may also help to identify those pa-
tients who may be at risk of developing secondary brain damage due to critical
illness [215, 216, 217]. Most inﬂammatory and immunological CSF biomarkers
are, according to the introductory deﬁnition, “process biomarkers”.
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Proteomics 2D gel electrophoresis is a well established technique that al-
lows for separation of proteins according to molecular mass and charge. With
the advent of mass spectroscopy, 2D gel electrophoresis has been re-employed
to identify potential new biomarkers. Conti et al. found the acute phase proteins
alpha-1 antitrypsin, haptoglobin 1 alpha1, alpha2 and beta to be increased in
the CSF following TBI [218]. Interestingly the carboxyl–terminal portion of ﬁb-
rinogen beta was only elevated in the CSF of patients with TBI, suggesting
increased ﬁbrinolysis in these patients [218]. Gao et al. have recently con-
ﬁrmed the results by Conti et al. Acute phase proteins and haptoglobins were
increased in the CSF of patients with nTBI [219]. The authors also found CSF
levels of prostaglandin–D(2)–synthetase and cystatin C to be higher in patients
with iTBI when compared to patients with nTBI [219].
Burgess et al. performed a comparative study on ante- and postmortem
CSF in in comparison to CSF in order to identify putative new CSF candidate
biomarkers indicative for brain cell death [220]. These authors compiled an
impressive list of 299 potential CSF biomarkers [220]. In a cell–culture model
Siman et al. described release of over 60 cytoskeletal proteins from neurons
[161].
7 Pitfalls
A range of pre–analytical and analytical pitfalls deserve to be mentioned. The
CSF sampling technique, transport, time to storage and storage conditions
should be standardised. Ideally one would like to have three serial tubes of CSF
with at least 3 mL collected in a polypropylene tube. The reason for this is that
most proteins are charged negatively and would bind to the positively charged
surface of polystyrene or glass tubes, potentially leading to artiﬁcially low CSF
levels of the biomarker in question. Samples should be spun down and the su-
pernatant stored at least at -20◦C within one hour of collection. Longer trans-
port and sample handling times may cause degradation of the biomarker and
cause artiﬁcial results. Needless to say, sample storage in multiple aliquots
of a small volume (e.g. 500 L to 1 mL in e.g. 1.5 mL Eppendorf tubes) al-
lows for easy future analysis of several biomarkers, including the sending out
of samples to other laboratories and avoiding repeated freeze–thaw cycles.
There are some simple analytical facts which help to guide the analysis of
data. For example, the intra–assay coefﬁcient of variation (CV = SD
mean  100)
of a technique indicates the degree of variation which may occur between per-
formance of the same assay on the same sample at different time–points. For
routine laboratory work a CV of less than 10% is desirable. Many assays de-
veloped for research are still in their infancy and will not achieve this target.
This may not be critical as long as one remembers that an assay with a CV of,
say, 20% cannot reliably be used to detect a difference between two groups (or
27two subsequent samples) of, say, 4%. As a rule of thumb, the CV of a method
determines how much trust one puts into the statistical result on group differ-
ences. In order to make publications comparable it is desirable to have some
basic information about the methods such as the detection limit, sensitivity, lin-
ear range, parallelism and stability of the biomarker. For example it should
come as no surprise if levels of a biomarker that is stable for one month at 4◦C
are higher in samples from a study group, compared to “historical samples”
from a control group collected 5 years earlier. Well–deﬁned upper reference
values determined in a large reference cohort are helpful for future comparison
as they act as a benchmark. All analysis should be performed with the analyst
being blinded to all other information.
Most patients in neurocritical care will receive large quantities of intravas-
cular ﬂuids. Levesl of many biomarkers in the blood may be reduced simply
because of an i.v. ﬂuid–related dilution effect. In situations like this one can
use an addiotional measure, e.g. the haemotocrit as guidance for data analy-
sis.
Substantial suggestions for future biomarker studies have been made by
McShane et al. (see Table 1 in reference [9]) and offer themselves for adaption
to other medical subspecialties.
8 Conclusion
Table 2 summarises the CSF biomarkers which were related to outcome data
and may therefore be of value for improving the prognostic accuracy in acute
CNS disease. This list is small compared to Table 1 and the inclusion of –
spectrin may be debatable [161]. Biomarker stability, accuracy of the analytical
technique employed, study design and the pitfalls discussed above all take their
toll. Two studies compared the prognostic accuracy of a CSF biomarker with
the GCS [1, 2] in TBI [133] or established neurophysiological criteria [221] in
GBS [130]. Both found CSF biomarkers to give the most accurate prognosis
[133, 130].
The challenge for future studies is to combine CSF biomarkers with solid
outcome data.
28Table 2: Summary table for those CSF biomarkers which were related to clinical outcome
scales and may be of help in improving the prognostic accuracy in acute CNS disorders.
CSF biomarker Disease Outcome measure Reference
-spectrin 7 TBI GOS [159, 163]
ABP 1-42 SAH GOS [124]
ABP 1-42 TBI GOS [138] 8
ApoE SAH GOS [125]
Circulating nucleic acids stroke modiﬁed Rankin [88]
F2-isoprostanes SAH GOS [206]
F2-isoprostanes TBI GOS [209]
FFA TBI, SAH, stroke GOS [201]
GFAP SAH Survival [54]
Glutamate TBI GOS [197]
MBP SAH GOS [68]
MBP Stroke short term prognosis [78]
MBP TBI GOS [63]
NOx TBI & SAH Survival [38]
NSE GBS disease duration [100]
NSE cardiac arrest functional outcome [101]
NSE iTBI Survival, GOS [72, 105] 9
NfH GBS F–score, MRCS [130]
NfH & NfL SAH GOS [39, 40]
NfL Cardiac arrest GOS [41]
S100B SAH GOS [125]
S100B TBI GOS [102, 123] 10
S100B iTBI GOS [105]
Tau GBS F–score [128]
Tau TBI GOS [133, 131]
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